US2472133A
(en)
|
1947-03-20 |
1949-06-07 |
Du Pont |
Thiophanthraquinone derivatives
|
SU1049490A1
(en)
|
1982-05-18 |
1983-10-23 |
Ордена Трудового Красного Знамени Институт Химии Ан Мсср |
(3ar,9as,9bs)-6,6,9a-trimethyltransperhydronaphth(2,2-b)-furan as scent component of perfumery composition
|
JPS6112632A
(en)
*
|
1984-06-27 |
1986-01-21 |
Eisai Co Ltd |
Composition containing fat-soluble drug
|
JPS6199787A
(en)
|
1984-10-19 |
1986-05-17 |
株式会社日立製作所 |
Band type piping supporter
|
JPS63196576A
(en)
|
1987-02-10 |
1988-08-15 |
Tetsuo Ikegawa |
Furalnaphthoquinone derivative and carcinostatic agent and production thereof
|
US5846534A
(en)
|
1988-02-12 |
1998-12-08 |
British Technology Group Limited |
Antibodies to the antigen campath-1
|
JPH04139177A
(en)
|
1989-12-28 |
1992-05-13 |
Dainippon Ink & Chem Inc |
Furalbenzoquinone derivative, its production and carcinostatic agent
|
EP0757292B1
(en)
|
1990-07-10 |
1999-12-22 |
Canon Kabushiki Kaisha |
Electrophotographic photosensitive member
|
TW252136B
(en)
|
1992-10-08 |
1995-07-21 |
Ciba Geigy |
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
DK0669836T3
(en)
|
1992-11-13 |
1996-10-14 |
Idec Pharma Corp |
Therapeutic use of chimeric and radiolabeled antibodies and human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma
|
DE4322826A1
(en)
*
|
1993-07-08 |
1995-01-12 |
Galenik Labor Freiburg Gmbh |
Pharmaceutical preparation
|
US5595721A
(en)
|
1993-09-16 |
1997-01-21 |
Coulter Pharmaceutical, Inc. |
Radioimmunotherapy of lymphoma using anti-CD20
|
GB9603507D0
(en)
|
1996-02-20 |
1996-04-17 |
Isis Innovation |
Antibody variants
|
JP3598168B2
(en)
|
1996-03-18 |
2004-12-08 |
独立行政法人 科学技術振興機構 |
Antiviral agent
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
JPH1121284A
(en)
|
1997-06-30 |
1999-01-26 |
Kotobuki:Kk |
Furanonaphthoquinone derivative and medicine containing the same
|
JPH1165141A
(en)
|
1997-08-11 |
1999-03-05 |
Canon Inc |
Electrophotographic photoreceptor and process cartridge and electrophotographic apparatus each having this photoreceptor
|
US6174913B1
(en)
|
1998-06-05 |
2001-01-16 |
The University Of North Carolina At Chapel Hill |
Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
EP1897540A3
(en)
|
1999-01-27 |
2008-07-23 |
University Of South Florida |
Inhibition of STAT3 signal transduction for human cancer therapy
|
AU2736400A
(en)
|
1999-01-27 |
2000-08-18 |
University Of South Florida |
Inhibition of stat3 signal transduction for human cancer therapy
|
BRPI0009448B8
(en)
|
1999-04-01 |
2021-05-25 |
Univ Texas |
kit for use in treating a neoplasm in a mammal
|
US6482943B1
(en)
|
1999-04-30 |
2002-11-19 |
Slil Biomedical Corporation |
Quinones as disease therapies
|
JP3961827B2
(en)
|
1999-08-02 |
2007-08-22 |
エフ.ホフマン−ラ ロシュ アーゲー |
Novel selective retinoid agonist
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
ES2282133T3
(en)
|
1999-08-24 |
2007-10-16 |
Medarex, Inc. |
ANTIBODIES AGAINST HUMAN CTLA-4 AND ITS USES.
|
JP2001097860A
(en)
|
1999-09-29 |
2001-04-10 |
Japan Science & Technology Corp |
Anti-drug-resistant bacterium agent and anti-chlamydia agent
|
UA75055C2
(en)
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Benzoimidazole derivatives being used as antiproliferative agent, pharmaceutical composition based thereon
|
KR20010100194A
(en)
|
2000-03-13 |
2001-11-14 |
박호군 |
Composition and formulation for solubilization of various compounds and preparation method thereof
|
AU2001293995B2
(en)
|
2000-10-09 |
2005-10-13 |
Cytomx Therapeutics, Inc. |
Therapeutic antibodies
|
US7090843B1
(en)
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
US7998947B2
(en)
|
2001-03-28 |
2011-08-16 |
University Of South Florida |
Materials and methods for treatment of cancer and identification of anti-cancer compounds
|
GB0117696D0
(en)
|
2001-07-20 |
2001-09-12 |
Bradford Particle Design Plc |
Particle information
|
WO2003045357A1
(en)
|
2001-11-27 |
2003-06-05 |
Transform Pharmaceuticals, Inc. |
Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
|
US20030139466A1
(en)
|
2001-11-29 |
2003-07-24 |
Peritt David L. |
Methods for pretreating a subject with extracorporeal photopheresis
|
AU2003215524A1
(en)
|
2002-03-15 |
2003-09-29 |
Natimmune A/S |
Pharmaceutical compositions comprising mannose binding lectin
|
CA2481515C
(en)
|
2002-04-10 |
2013-10-01 |
Genentech, Inc. |
Anti-her2 antibody variants
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
EP2283869A3
(en)
|
2002-07-15 |
2012-06-27 |
Board of Regents, The University of Texas System |
Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer
|
US20060142271A1
(en)
|
2002-09-17 |
2006-06-29 |
Klaus Muller |
Novel lapacho compounds and methods of use thereof
|
CA2502552C
(en)
|
2002-10-17 |
2019-02-12 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
CL2003002353A1
(en)
|
2002-11-15 |
2005-02-04 |
Vertex Pharma |
COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
|
TWI323662B
(en)
|
2002-11-15 |
2010-04-21 |
Telik Inc |
Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
|
IS6633A
(en)
|
2002-11-22 |
2004-05-23 |
Omega Farma Ehf. |
Compositions of finasteride tablets
|
KR20060031809A
(en)
*
|
2003-06-09 |
2006-04-13 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
Compositions and methods for treating and diagnosing cancer
|
CN104059147A
(en)
|
2003-06-27 |
2014-09-24 |
艾默根佛蒙特有限公司 |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US20050049207A1
(en)
|
2003-09-03 |
2005-03-03 |
Kaufmann Doug A. |
Method of treating and preventing cancer
|
WO2005033048A2
(en)
|
2003-09-29 |
2005-04-14 |
The Johns Hopkins University |
Wnt pathway antagonists
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
JP4804357B2
(en)
|
2003-11-01 |
2011-11-02 |
メルク パテント ゲーエムベーハー |
Modified anti-CD52 antibody
|
SG148215A1
(en)
|
2003-12-02 |
2008-12-31 |
Cleveland Clinic Foundation |
Methods of protecting against radiation using flagellin
|
SI1701941T1
(en)
|
2003-12-11 |
2012-09-28 |
Univ Texas |
Compounds for treatment of cell proliferative diseases
|
DE10359828A1
(en)
|
2003-12-12 |
2005-07-28 |
Zoser B. Dr.Rer.Nat. Salama |
CHP gemcitabine combination agents and their use as antitumor agents, in particular anti-metastatic agents
|
CA2563305A1
(en)
|
2004-04-09 |
2005-11-24 |
University Of South Florida |
Combination therapies for cancer and proliferative angiopathies
|
JP2004224802A
(en)
|
2004-04-21 |
2004-08-12 |
Japan Science & Technology Agency |
Antibacterial agent
|
DK2287195T3
(en)
|
2004-07-01 |
2019-08-19 |
Innate Pharma |
PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND USE IN DIAGNOSTICS AND THERAPY
|
MX2007000265A
(en)
|
2004-07-02 |
2007-07-20 |
Icos Corp |
Compounds useful for inhibiting chk1.
|
JP2008507520A
(en)
|
2004-07-22 |
2008-03-13 |
ジェネンテック・インコーポレーテッド |
HER2 antibody composition
|
AU2005273704A1
(en)
|
2004-08-18 |
2006-02-23 |
Astrazeneca Ab |
Selected fused heterocyclics and uses thereof
|
CA2587276A1
(en)
|
2004-11-08 |
2006-05-18 |
Baxter International Inc. |
Nanoparticulate compositions of tubulin inhibitor compounds
|
AU2005309019A1
(en)
|
2004-11-24 |
2006-06-01 |
Novartis Ag |
Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
|
WO2006065894A2
(en)
|
2004-12-14 |
2006-06-22 |
University Of South Florida |
Methods for inhibiting stat3 signaling in immune cells
|
WO2006071812A2
(en)
|
2004-12-23 |
2006-07-06 |
H. Lee Moffitt Cancer Center And Research Institute |
Platinum iv complex inhibitor
|
WO2006091837A2
(en)
|
2005-02-25 |
2006-08-31 |
The Regent Of The University Of Michigan |
Small molecule inhibitors of stat3 and the uses thereof
|
JP2006248978A
(en)
|
2005-03-10 |
2006-09-21 |
Mebiopharm Co Ltd |
New liposome preparation
|
JP2006290871A
(en)
|
2005-03-16 |
2006-10-26 |
Taheebo Japan Kk |
Compound exhibiting anti-cancer property, intermediate therefor and method for producing the same
|
US20060252073A1
(en)
|
2005-04-18 |
2006-11-09 |
Regents Of The University Of Michigan |
Compositions and methods for the treatment of cancer
|
CN109485727A
(en)
|
2005-05-09 |
2019-03-19 |
小野药品工业株式会社 |
The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody
|
MX2007015942A
(en)
|
2005-07-01 |
2008-03-07 |
Medarex Inc |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1).
|
US20070009532A1
(en)
|
2005-07-06 |
2007-01-11 |
Branimir Sikic |
Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
|
UA96139C2
(en)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Anti-neuropilin-1 (nrp1) antibody
|
AR057579A1
(en)
|
2005-11-23 |
2007-12-05 |
Merck & Co Inc |
SPIROCICLICAL COMPOUNDS AS INHIBITORS OF ACETYLASE HISTONE (HDAC)
|
JP2007145680A
(en)
|
2005-11-30 |
2007-06-14 |
Idemitsu Kosan Co Ltd |
Hydrogen generating material and hydrogen generating method
|
CA2628728A1
(en)
|
2005-12-24 |
2007-07-05 |
Biotica Technology Ltd. |
21-deoxymacbecin analogues useful as antitumor agents
|
US20090012075A1
(en)
|
2006-01-12 |
2009-01-08 |
Miller Thomas A |
Fluorinated Arylamide Derivatives
|
CA2635797C
(en)
|
2006-02-09 |
2015-03-31 |
Macusight, Inc. |
Stable formulations, and methods of their preparation and use
|
US20070243192A1
(en)
|
2006-02-21 |
2007-10-18 |
Regents Of The University Of Michigan |
Growth hormone receptor antagonist cancer treatment
|
WO2007095753A1
(en)
|
2006-02-24 |
2007-08-30 |
Merck Frosst Canada Ltd. |
2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles
|
JP5654233B2
(en)
|
2006-03-31 |
2015-01-14 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
Orally bioavailable caffeic acid-related anticancer agents
|
US20070238770A1
(en)
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
WO2008094321A2
(en)
|
2006-10-04 |
2008-08-07 |
Universtiy Of South Florida |
Akt sensitization of cancer cells
|
WO2008077062A2
(en)
|
2006-12-19 |
2008-06-26 |
Board Of Regents, The University Of Texas System |
Suppression of stat3 reactivation after src kinase inhibition to treat cancer
|
JP4077863B1
(en)
|
2007-05-31 |
2008-04-23 |
タヒボジャパン株式会社 |
Process for producing optically active 2- (1-hydroxyethyl) -5-hydroxynaphtho [2,3-b] furan-4,9-dione having anticancer activity
|
DK2170959T3
(en)
|
2007-06-18 |
2014-01-13 |
Merck Sharp & Dohme |
ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1
|
CN101842381A
(en)
|
2007-08-27 |
2010-09-22 |
波士顿生物医药公司 |
Composition of asymmetric RNA duplex as microrna mimetic or inhibitor
|
HUE027443T2
(en)
|
2007-09-10 |
2016-10-28 |
Boston Biomedical Inc |
A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
WO2009060282A2
(en)
|
2007-11-06 |
2009-05-14 |
Orchid Research Laboratories Limited |
Stilbene derivatives as pstat3/il-6 inhibitors
|
JP2011506319A
(en)
*
|
2007-12-06 |
2011-03-03 |
デュレクト コーポレーション |
Useful methods for the treatment of pain, joint inflammation symptoms, or inflammation associated with chronic diseases
|
US20100297118A1
(en)
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
AU2009288289B2
(en)
|
2008-08-25 |
2012-11-08 |
Amplimmune, Inc. |
PD-1 antagonists and methods of use thereof
|
TWI686405B
(en)
|
2008-12-09 |
2020-03-01 |
建南德克公司 |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
CA2939492C
(en)
|
2009-05-13 |
2019-03-19 |
Genzyme Corporation |
Anti-human cd52 immunoglobulins
|
US8267122B2
(en)
|
2009-06-30 |
2012-09-18 |
Ge Aviation Systems Llc |
Method and systems for bleed air supply
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
Simultaneous inhibition of pd-l1/pd-l2
|
RS60033B1
(en)
|
2009-11-24 |
2020-04-30 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
WO2011084694A1
(en)
|
2009-12-17 |
2011-07-14 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Stabilized stat3 decoy oligonucleotides and uses therefor
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
PH12018501083A1
(en)
|
2010-03-04 |
2019-02-18 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
EP3295796A1
(en)
|
2010-03-19 |
2018-03-21 |
1Globe Biomedical Co., Ltd. |
Novel compounds and compositions for targeting cancer stem cells
|
CA2793526C
(en)
|
2010-03-19 |
2018-05-01 |
Boston Biomedical, Inc. |
Naphthofuran compounds and compositions for targeting cancer stem cells
|
BR112012023660B8
(en)
*
|
2010-03-19 |
2021-05-25 |
Boston Biomedical Inc |
uses of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, for the treatment of cancer
|
AU2015218436B9
(en)
|
2010-03-19 |
2017-03-09 |
Boston Biomedical, Inc. |
Novel Methods For Targeting Cancer Stem Cells
|
JP5208239B2
(en)
|
2010-09-29 |
2013-06-12 |
タヒボジャパン株式会社 |
Novel production method of anticancer active tricyclic compounds by alkyne coupling
|
US9919017B2
(en)
*
|
2011-02-01 |
2018-03-20 |
Kaneka Corporation |
Biologically active substance-containing water-solubilizing preparation and method for producing the same
|
CN103402993A
(en)
|
2011-03-04 |
2013-11-20 |
舟山海中洲新生药业有限公司 |
Novel esters of 4,9-dihydroxy-naphtho[2,3-b]furans for disease therapies
|
KR102031020B1
(en)
|
2011-03-31 |
2019-10-14 |
머크 샤프 앤드 돔 코포레이션 |
Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
|
US8977803B2
(en)
|
2011-11-21 |
2015-03-10 |
Western Digital Technologies, Inc. |
Disk drive data caching using a multi-tiered memory
|
WO2013166618A1
(en)
|
2012-05-08 |
2013-11-14 |
Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. |
PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
|
US9212224B2
(en)
|
2012-05-15 |
2015-12-15 |
Bristol-Myers Squibb Company |
Antibodies that bind PD-L1 and uses thereof
|
WO2013172918A1
(en)
|
2012-05-15 |
2013-11-21 |
University Of Southern California |
Ksr1 gene polymorphism for use in predicting outcome and therapy selection
|
UY34887A
(en)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
|
SG11201508358RA
(en)
|
2013-04-09 |
2015-11-27 |
Boston Biomedical Inc |
2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
|
JP6199787B2
(en)
|
2014-03-28 |
2017-09-20 |
京セラドキュメントソリューションズ株式会社 |
Image forming apparatus
|
DK3043778T3
(en)
|
2013-09-13 |
2017-11-27 |
Bayer Pharma AG |
PHARMACEUTICAL COMPOSITIONS CONTAINING REFAMETINIB
|
TW201622731A
(en)
|
2014-04-08 |
2016-07-01 |
泰瓦藥品工業有限公司 |
Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir and a monolithic tablet comprising darunavir and ritonavir
|
ES2792851T3
(en)
|
2014-06-09 |
2020-11-12 |
Kyoto Pharma Ind |
Naphthofuran derivatives for use as antineoplastic agents
|
JP2016016973A
(en)
|
2014-07-10 |
2016-02-01 |
株式会社リコー |
Sheet processing device
|
WO2016030455A1
(en)
|
2014-08-28 |
2016-03-03 |
Medimmune Limited |
Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
|
CN106470697B
(en)
|
2014-09-16 |
2019-10-25 |
兴盟生物医药(苏州)有限公司 |
Anti-egfr antibodies with and application thereof
|
US20180098959A1
(en)
|
2015-04-17 |
2018-04-12 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
EA201792287A1
(en)
|
2015-04-17 |
2018-03-30 |
Бостон Биомедикал, Инк. |
METHODS OF TREATING CANCER
|
AU2016249157A1
(en)
|
2015-04-17 |
2017-11-02 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
MX2017013816A
(en)
|
2015-04-27 |
2018-11-12 |
Boston Biomedical Inc |
Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor.
|
US20180140572A1
(en)
|
2015-06-03 |
2018-05-24 |
Boston Biomedical, Inc. |
Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
|
US20190076392A1
(en)
|
2016-01-20 |
2019-03-14 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
US20190375723A1
(en)
|
2016-11-22 |
2019-12-12 |
Boston Biomedical, Inc. |
New Naphtho[2,3-B]Furan Derivatives
|
WO2018183089A1
(en)
|
2017-03-30 |
2018-10-04 |
Boston Biomedical, Inc. |
Compositions for treating and/or preventing cancer
|
CA3062656A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|